SNPX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	14 402.00
Average Volume	50 236.00
Market Cap	4.95M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0.0550 (1.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Singer William S.	Buy	800	Stock Option (Right to Buy)
2024-04-08	Silverman Joshua	Buy	800	Stock Option (Right to Buy)
2024-04-08	Schechter Jonathan	Buy	800	Stock Option (Right to Buy)
2024-04-08	Bernstein Bruce	Buy	800	Stock Option (Right to Buy)
2023-03-29	Schechter Jonathan	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
74.99
Last 71 transactions
Buy: 1 845 200 \| Sell: 283 116

Volume Correlation

Long: 0.06 (neutral)

Short: -0.61 (weak negative)

Signal:(50.83) Neutral

Synaptogenix, Inc. Correlation

10 Most Positive Correlations
GOSS	0.958
VORB	0.946
BCAB	0.946
THTX	0.944
XFOR	0.943
FATE	0.942
NVTSW	0.941
RIVN	0.939
NCBS	0.938
ISPO	0.938

10 Most Negative Correlations
NWLI	-0.967
AMYT	-0.967
EZGO	-0.959
RXDX	-0.956
TACO	-0.956
MLCO	-0.955
LUNA	-0.954
HZNP	-0.953
EXAS	-0.953
MLVF	-0.953

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Synaptogenix, Inc. Correlation - Currency/Commodity

-0.02
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

0.09
( neutral )

0.13
( neutral )

Synaptogenix, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-6 347.00 (0.00 %)
EPS:	$-12.96

Q4	2023
Revenue:	$0
Gross Profit:	$-1 210.00 (0.00 %)
EPS:	$-1.030

Q3	2023
Revenue:	$0
Gross Profit:	$-1 723.00 (0.00 %)
EPS:	$-0.0338

Q2	2023
Revenue:	$0
Gross Profit:	$-1 724.00 (0.00 %)
EPS:	$-0.560

Financial Reports:

No articles found.

Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.